Reports Q1 revenue $234.4M, consensus $220.2M. “The strength of our first quarter performance was driven by more than 20% worldwide sales growth, including our highest quarter ever outside the United States,” said John Sheridan, CEO. “We are creating new possibilities for people living with diabetes, while delivering record results that align with our 2025 and long-term financial goals for sustained, double-digit sales growth and profitability.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- TNDM Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Tandem Diabetes price target lowered to $45 from $55 at RBC Capital
- Hold Rating for Tandem Diabetes Care Amid Competitive and Macroeconomic Challenges
- Tandem Diabetes initiated with a Neutral at Mizuho
- Tandem announces publication of results from trial of Control-IQ+ AID technology